5-hydroxytryptophan has been researched along with Obesity in 14 studies
5-Hydroxytryptophan: The immediate precursor in the biosynthesis of SEROTONIN from tryptophan. It is used as an antiepileptic and antidepressant.
5-hydroxytryptophan : A tryptophan derivative that is tryptophan substituted by a hydroxy group at position 5.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous observations have shown that oral administration of 5-hydroxytryptophan (5-HTP) without dietary prescriptions causes anorexia, decreased food intake, and weight loss in obese subjects." | 5.07 | Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan. ( Antonucci, F; Cangiano, C; Cascino, A; Ceci, F; Del Ben, M; Laviano, A; Muscaritoli, M; Rossi-Fanelli, F, 1992) |
| "Overweight or obesity is strongly associated with comorbidities such as type 2 diabetes mellitus, hypertension, heart disease, gall bladder disease, and sleep apnea." | 2.41 | A functional food product for the management of weight. ( Bell, SJ; Goodrick, GK, 2002) |
| " 5-HTP is well absorbed from an oral dose, with about 70 percent ending up in the bloodstream." | 2.40 | 5-Hydroxytryptophan: a clinically-effective serotonin precursor. ( Birdsall, TC, 1998) |
| " Chronic administration of experimental ED40 of 5-HTP/30 mg/kg carbidopa + phentermine, but not 5-HTP/30 mg/kg carbidopa + diethylpropion, increased the mitral valve leaflets area." | 1.62 | Anorectic interaction and safety of 5-hydroxytryptophan/carbidopa plus phentermine or diethylpropion in rat. ( Flores-Murrieta, FJ; Huerta-Cruz, JC; Lara-Padilla, E; Limón-Bernal, E; Reyes-García, JG; Roa-Coria, JE; Rocha-González, HI; Ruíz-Velasco, IRC; Zúñiga-Romero, Á, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (28.57) | 18.7374 |
| 1990's | 5 (35.71) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Maffei, ME | 1 |
| Limón-Bernal, E | 1 |
| Roa-Coria, JE | 1 |
| Zúñiga-Romero, Á | 1 |
| Huerta-Cruz, JC | 1 |
| Ruíz-Velasco, IRC | 1 |
| Flores-Murrieta, FJ | 1 |
| Lara-Padilla, E | 1 |
| Reyes-García, JG | 1 |
| Rocha-González, HI | 1 |
| Hendricks, EJ | 1 |
| Rothman, RB | 1 |
| Greenway, FL | 1 |
| Medeiros, MA | 1 |
| Costa-e-Sousa, RH | 1 |
| Olivares, EL | 1 |
| Côrtes, WS | 1 |
| Reis, LC | 1 |
| Lindström, P | 1 |
| Sehlin, J | 2 |
| Birdsall, TC | 1 |
| Bell, SJ | 1 |
| Goodrick, GK | 1 |
| Cangiano, C | 3 |
| Ceci, F | 3 |
| Cascino, A | 3 |
| Del Ben, M | 3 |
| Laviano, A | 2 |
| Muscaritoli, M | 3 |
| Antonucci, F | 1 |
| Rossi-Fanelli, F | 2 |
| Cairella, M | 2 |
| Koulu, M | 1 |
| Huupponen, R | 1 |
| Hänninen, H | 1 |
| Pesonen, U | 1 |
| Rouru, J | 1 |
| Seppälä, T | 1 |
| Sibilia, L | 1 |
| Rossi Fanelli, F | 1 |
| Gylfe, E | 1 |
| Hellman, B | 1 |
| Taljedal, IB | 1 |
| Lernmark, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Daily Supplementation of 5-HTP on Body Composition, a Randomized Investigation[NCT05216406] | 65 participants (Actual) | Interventional | 2021-01-01 | Completed | |||
| Long-term Phentermine Pharmacotherapy: An Investigation for Symptoms of Dependence, Cravings, or Withdrawal[NCT01402674] | 269 participants (Actual) | Interventional | 2011-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for 5-hydroxytryptophan and Obesity
| Article | Year |
|---|---|
5-Hydroxytryptophan (5-HTP): Natural Occurrence, Analysis, Biosynthesis, Biotechnology, Physiology and Toxicology.
Topics: 5-Hydroxytryptophan; Animals; Biotechnology; Humans; Mental Disorders; Obesity; Serotonin Syndrome; | 2020 |
5-Hydroxytryptophan: a clinically-effective serotonin precursor.
Topics: 5-Hydroxytryptophan; Contraindications; Depressive Disorder; Fibromyalgia; Headache; Humans; Obesity | 1998 |
A functional food product for the management of weight.
Topics: 5-Hydroxytryptophan; Anti-Obesity Agents; Appetite; Chromium; Dietary Carbohydrates; Dietary Fiber; | 2002 |
3 trials available for 5-hydroxytryptophan and Obesity
| Article | Year |
|---|---|
Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan.
Topics: 5-Hydroxytryptophan; Adult; Dietary Carbohydrates; Dietary Proteins; Energy Intake; Female; Humans; | 1992 |
Effects of 5-hydroxytryptophan on eating behavior and adherence to dietary prescriptions in obese adult subjects.
Topics: 5-Hydroxytryptophan; Adult; Anorexia; Diet, Reducing; Dietary Carbohydrates; Feeding Behavior; Femal | 1991 |
The effects of oral 5-hydroxytryptophan administration on feeding behavior in obese adult female subjects.
Topics: 5-Hydroxytryptophan; Administration, Oral; Adult; Double-Blind Method; Feeding Behavior; Female; Hum | 1989 |
8 other studies available for 5-hydroxytryptophan and Obesity
| Article | Year |
|---|---|
Anorectic interaction and safety of 5-hydroxytryptophan/carbidopa plus phentermine or diethylpropion in rat.
Topics: 5-Hydroxytryptophan; Animals; Appetite Depressants; Biomarkers, Pharmacological; Carbidopa; Cardiova | 2021 |
How physician obesity specialists use drugs to treat obesity.
Topics: 5-Hydroxytryptophan; Anti-Obesity Agents; Carbidopa; Drug Combinations; Drug Labeling; Drug Therapy, | 2009 |
A reassessment of the role of serotonergic system in the control of feeding behavior.
Topics: 5-Hydroxytryptophan; Animals; Electrolysis; Feeding Behavior; Fenclonine; Male; Microinjections; Obe | 2005 |
Mechanisms underlying the effects of 5-hydroxytryptamine and 5-hydroxytryptophan in pancreatic islets. A proposed role for L-aromatic amino acid decarboxylase.
Topics: 5-Hydroxytryptophan; Animals; Aromatic-L-Amino-Acid Decarboxylases; Calcium; Insulin; Islets of Lang | 1983 |
5-hydroxytryptophan.
Topics: 5-Hydroxytryptophan; Contraindications; Depressive Disorder; Fibromyalgia; Headache; Humans; Obesity | 1998 |
Hypothalamic neurochemistry and feeding behavioral responses to clonidine, an alpha-2-agonist, and to trifluoromethylphenylpiperazine, a putative 5-hydroxytryptamine-1B agonist, in genetically obese Zucker rats.
Topics: 5-Hydroxytryptophan; Adrenergic alpha-Agonists; Animals; Aromatic Amino Acid Decarboxylase Inhibitor | 1990 |
Amino acid conversion into 5-hydroxytryptamine in pancreatic beta-cells.
Topics: 5-Hydroxytryptophan; Animals; Autoradiography; Carbon Isotopes; Centrifugation; Chromatography, Thin | 1973 |
The significance of 5-hydroxytryptamine for insulin secretion in the mouse.
Topics: 5-Hydroxytryptophan; Animals; Bromine; Drug Antagonism; Glucose; Hyperglycemia; In Vitro Techniques; | 1971 |